Position paper by Swissmedic and swissethics on decentralized clinical trials (DCTs) with medicinal products

Publications swissethics

Annual reports and other publications of swissethics

Updated documents

List of documents recently updated by swissethics


NO to the ban on animal and human experimentation: swissethics rejects the federal popular initiative «Yes to the ban on animal and human experiments» of February 13, 2022


The Federal Act on Research involving Human Beings (HRA) thoroughly regulates clinical trials and research projects in Switzerland. swissethics is committed to clinical research that meets the highest ethical and scientific standards.

Acceptance of the initiative would create ethically questionable situations. All clinical trials would then be banned in Switzerland, medical care in Switzerland would be put at risk and patients would no longer benefit from new medicines and medical innovations. This is ethically unacceptable.

swissethics supports the positions of unimedsuisse, SAMW and SCTO. These provide further information and arguments on the compelling need to reject this initiative (in German link, in French link).

Comprehensibility as an ethical dimension


The comprehensibility of the patient information and consent forms is a prerequisite for good, fair and correct information concerning participation in clinical trials and research projects. Unfortunately, not all such documents submitted to ethics committees fulfil this requirement to the desired and necessary extent.

Read more

Position paper by Swissmedic and swissethics on decentralized clinical trials (DCTs) with medicinal products


The development of novel technologies and digitalization in the field of therapeutic products offers new opportunities. Through the use of these technologies in clinical trials, it is possible that study visits do not always have to be carried out in the hospital, but can also take place at home.

Read more

swissethics publishes the updated templates of the protocols for research projects of further use


The further use of data and samples for research purposes accounts for an increasingly growing proportion of all research projects conducted in Switzerland. Questions on Big Data and data sharing, e.g. also in the context of large national projects such as SPHN, are often in the foreground.

Read more

Federal Council breaks off negotiations on the institutional agreement with the EU: Consequences for the clinical research of medical devices in Switzerland


On May 26, the Medical Device Regulation (MDR) at EU level and in Switzerland the ordinance for clinical trials of medical devices (ClinO-MD) came into force. At the same time, Switzerland broke off the negotiations on the framework agreement with the EU.

Read more